Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China
A 12-month, Open-label, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of OZURDEX® Implant 700 µg (Dexamethasone) on Patients With Macular Edema Secondary to Retinal Vein Occlusion in China (YANGTZE Study)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100730
- Beijing Tongren Hospital, CMU /ID# 233608
-
Changsha Hunan, China, 410008
- The First Xiangya Hospital of Central South University /ID# 233627
-
Dalian, China, 116011
- The First Affiliated Hospital of Dalian Medical University /ID# 233688
-
Jinan, China, 250012
- Qilu Hospital of Shandong University /ID# 233605
-
Shanghai, China, 200031
- The Eye and ENT Hospital Affiliated of Fudan Univesity /ID# 233666
-
Shanghai, China, 200080
- Shanghai General Hospital /ID# 233579
-
Shantou, China, 515041
- Joint Shantou International Eye Center of Shantou University and The Chinese Uni /ID# 233580
-
Tianjin, China, 300020
- Tianjin Eye Hospital /ID# 233581
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Peking Union Medical College Hospital /ID# 233616
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Inclusion Criteria:
- Patient diagnosed with macular edema due to RVO (either BRVO or CRVO, non-ischemic)
- Retinal thickness ≥ 300 μm by SD-OCT in the central 1 mm macular subfield of the study eye at the Screening visit
- BCVA score of 19 to 73 letters (approximately 20/400 to 20/40 Snellen equivalent) in the study eye measured by ETDRS method at Screening
- < 3 months of macular edema duration
- Treatment-naive patients (ie, have not previously received any treatment for macular edema secondary to RVO)
Exclusion Criteria:
- Uncontrolled systemic disease
- Presence of/history of any ocular condition other than macular edema that affects visual acuity (eg, cataract, severe macular ischemia, foveal atrophy, age-related macular degeneration, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass syndrome, prior macular detachment)
- Any of the following ≤ 3 months before study entry or anticipated need within the coming 3 months:
- Intraocular surgery
- Laser photocoagulation
- Intraocular injection
- Periocular steroid injection
- Vitrectomized eye
- Aphakic eyes with ruptured posterior lens capsule or presence of an ACIOL, iris or transscleral fixated intraocular lens
- History of marked IOP elevation in response to steroid treatment that (a) required IOP-lowering treatment, (b) resulted in a >10 mm Hg increase in IOP from predose, or (c) resulted in IOP >25 mm Hg
- History of glaucoma or ocular hypertension (IOP > 21 mm Hg), or optic nerve head change consistent with glaucoma damage, and/or glaucomatous visual field loss in the study eye (patients with a history of previous angle closure that has been successfully treated with either a laser or surgical peripheral iridotomy [PI] are allowed as long as the visual fields have been stable for > 1 year prior to study entry and the patient has been and can be safely dilated).
- Any active ocular infection (i.e., bacterial, viral, parasitic, or fungal) in either eye at the Screening visit
- Female patients who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using a reliable means of contraception
- Any condition that may interfere or preclude participation in the study
- Use of systemic steroids (e.g., oral, intravenous, intramuscular, epidural, rectal, or extensive dermal) within 1 month prior to Baseline or anticipated use at any time during the study (inhaled, intranasal, and intra-articular/intrabursal corticosteroids are allowed)
- Use of immunosuppressants, immunomodulators, antimetabolites, and/or alkylating agents within 3 months prior to Baseline or anticipated use at any time during the study
- Use of warfarin or heparin within 2 weeks prior to Baseline or anticipated use within the study period
- Known allergy, hypersensitivity or contraindication to the study medication, its components, fluorescein or povidone iodine
- Current enrollment in another drug or device study within 30 days prior to Baseline
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Study Eye
OZURDEX implant 700 μg
|
Implant 700 μg
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean change in visual acuity from Baseline
Time Frame: At Month 6
|
Determined by best corrected visual acuity (BCVA)
|
At Month 6
|
|
Proportion of patients with a BCVA improvement of 15 letters or more compared to Baseline
Time Frame: At Month 6
|
Measured using the ETDRS visual acuity protocol
|
At Month 6
|
|
BCVA average change from Baseline in area under the curve (AUC) analysis
Time Frame: At Month 6
|
At Month 6
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean change from Baseline in BCVA
Time Frame: After first follow-up visit, at each injection, and at Month 12
|
After first follow-up visit, at each injection, and at Month 12
|
|
|
Mean change from Baseline in Central Retinal Thickness (CRT)
Time Frame: At Months 6 and 12
|
At Months 6 and 12
|
|
|
Mean change from Baseline in the National Eye Institute (NEI) Visual Function Questionnaire (VFQ)-25
Time Frame: At Months 6 and 12
|
25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question.
All items are scored so that a high score represents better functioning.
Original numeric values from the survey will be recoded with the worst and best possible scores set at 0 and 100 points, respectively.
In this format, scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.
|
At Months 6 and 12
|
|
Mean number of OZURDEX injections
Time Frame: During the 12-month study
|
During the 12-month study
|
|
|
Mean retreatment interval in months
Time Frame: During the 12-month study
|
During the 12-month study
|
|
|
Proportion of patients with 2nd injection
Time Frame: During the 12-month study
|
During the 12-month study
|
|
|
Proportion of patients with 3rd injection
Time Frame: During the 12-month study
|
During the 12-month study
|
|
|
Time to 2nd injection
Time Frame: During the 12-month study
|
During the 12-month study
|
|
|
Time to 3rd injection
Time Frame: During the 12-month study
|
During the 12-month study
|
|
|
Correlation between the change of BCVA and extent of leak by fluorescein angiography (FA)
Time Frame: At Month 6
|
At Month 6
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Embolism and Thrombosis
- Venous Thrombosis
- Thrombosis
- Macular Degeneration
- Macular Edema
- Retinal Vein Occlusion
- Edema
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protease Inhibitors
- Dexamethasone
- Dexamethasone acetate
- BB 1101
Other Study ID Numbers
Other Study ID Numbers
- CMO-MA-EYE-0575
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.